secwatch / observer

8-K filed June 11, 2024, 7:59 PM ET ticker CCI CIK 0001051470

other material confidence high sentiment positive materiality 0.75

Crown Castle restructures Fiber segment, cuts headcount >10%, lowers capex $275-325M

CROWN CASTLE INC.

Restructuring includes >10% headcount reduction and office closures; expects $110M total charges ($45M severance, $65M facilities).
Fiber segment capex reduced $275M-325M in 2024, focusing on higher-return on-net/near-net investments.
Annualized run-rate cost savings ~$100M, with ~$60M expected in 2024 from staffing and operational changes.
Strategic review of fiber business remains active and ongoing; small cell node additions cut by 3,000-5,000 in 2024.
Company still expects double-digit small cell revenue growth and 2% fiber solutions organic growth in 2024.

item 2.05 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001051470-24-000174
form_type: 8-K
ticker: CCI
cik: 0001051470
company_name: CROWN CASTLE INC.
filed_at: 2024-06-11T23:59:59+00:00
discovered_at: 2026-05-14T18:03:17.051936+00:00
generated_at: 2026-06-01T04:58:39.519540+00:00
sec_items: ["2.05", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001051470-24-000174
json_url: https://secwatch.observer/filing/0001051470-24-000174.json
markdown_url: https://secwatch.observer/filing/0001051470-24-000174.md
text_url: https://secwatch.observer/filing/0001051470-24-000174.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1051470/000105147024000174/0001051470-24-000174-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1051470/000105147024000174/cci-20240611.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Mid-America Apartments, L.P.

MAA May 2026 blended rents highest in 2 years; repurchased $50M shares

Mid-America Apartments, L.P. June 1, 2026, 4:20 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001051470-24-000174

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.